Biodexa Pharmaceuticals Announces First Patient Dosed In Phase 2 Investigator-Initiated Trial Of Tolimidone For Type 1 Diabetes At University Of Alberta, Evaluating Insulin And Glucose Markers Across Three Dose Groups with Potential For Study Expansion

Biodexa Announces Recruitment of First Patient

in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D").

The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.